Impact of adverse events-associated dose modifications of PARP inhibitors on treatment outcomes in primary ovarian cancer.

2 B), although the survival curves remained separated, the difference did not reach statistical significance (Log-rank P = 0.099).

also in 111,027 other papers

2 C), the dose reduction/interruption group exhibited an intermediate survival trajectory, which appeared superior to the permanent discontinuation group but showed a trend toward inferior PFS compared to the dose-maintenance group.

also in 53,322 other papers